Opaganib, a novel, twice-daily, oral medication developed by Israel’s RedHill Biopharma (see here previously) delivered a statistically significant increase in survival time in a United States Army Medical Research Institute of Infectious Diseases (USAMRIID) in vivo Ebola virus study
https://www.israel21c.org/drug-shows-promise-in-treating-often-fatal-ebola-disease/